222 related articles for article (PubMed ID: 19875578)
1. Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/mortality? Yes.
Bianchi C; Miccoli R; Daniele G; Penno G; Del Prato S
Diabetes Care; 2009 Nov; 32 Suppl 2(Suppl 2):S342-8. PubMed ID: 19875578
[No Abstract] [Full Text] [Related]
2. Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity or mortality? No.
Kassem SA; Raz I
Diabetes Care; 2009 Nov; 32 Suppl 2(Suppl 2):S337-41. PubMed ID: 19875577
[No Abstract] [Full Text] [Related]
3. Cardiovascular disease and oral agent glucose-lowering therapies in the management of type 2 diabetes.
Home P
Diabetes Technol Ther; 2012 Jun; 14 Suppl 1():S33-42. PubMed ID: 22650223
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular risks associated with second-line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study.
Chang YC; Chuang LM; Lin JW; Chen ST; Lai MS; Chang CH
Diabet Med; 2015 Nov; 32(11):1460-9. PubMed ID: 25970814
[TBL] [Abstract][Full Text] [Related]
6. [Therapies for newly-onset diabetic patients].
Kawamori R
Nihon Rinsho; 2005 Feb; 63 Suppl 2():525-32. PubMed ID: 15779435
[No Abstract] [Full Text] [Related]
7. [Current methods of glucose metabolism control in diabetes mellitus].
Scarpitta AM; Sinagra D
Recenti Prog Med; 2003 Jan; 94(1):31-40. PubMed ID: 12632998
[TBL] [Abstract][Full Text] [Related]
8. Diabetes mellitus. Medication update.
Slagle M
South Med J; 2002 Jan; 95(1):50-5. PubMed ID: 11827245
[No Abstract] [Full Text] [Related]
9. Role of oral anti-diabetic agents in modifying cardiovascular risk factors.
Shin JJ; Rothman J; Farag A; McFarlane SI; Sowers JR
Minerva Med; 2003 Dec; 94(6):401-8. PubMed ID: 14976468
[TBL] [Abstract][Full Text] [Related]
10. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
Hemmingsen B; Lund SS; Vaag A
Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological treatment of type 2 diabetes.
Hermans MP; Buysschaert M
Acta Clin Belg; 2004; 59(2):59-66. PubMed ID: 15224468
[No Abstract] [Full Text] [Related]
12. [Achieving better control of blood sugar--understanding of oral hypoglycemic agents according to their characteristics in pharmacological action mechanism (discussion)].
Kawamori R; Kadowaki T; Ishida H
Nihon Rinsho; 2004 Apr; 62(4):831-9. PubMed ID: 15106356
[No Abstract] [Full Text] [Related]
13. Safety of drugs commonly used to treat hypertension, dyslipidemia, and Type 2 diabetes (the metabolic syndrome): part 2.
Marcus AO
Diabetes Technol Ther; 2000; 2(2):275-81. PubMed ID: 11469270
[TBL] [Abstract][Full Text] [Related]
14. Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes.
Johnson JA; Majumdar SR
Am Heart J; 2004 Dec; 148(6):e27; author reply e28. PubMed ID: 15632864
[No Abstract] [Full Text] [Related]
15. Vascular disease in diabetes and the effect of oral antidiabetic agents.
Marble A
Adv Metab Disord; 1973; 2():Suppl 2:539-47. PubMed ID: 4720384
[No Abstract] [Full Text] [Related]
16. The Diabetes Prevention Program.
Muniyappa R; El-Atat F; Aneja A; McFarlane SI
Curr Diab Rep; 2003 Jun; 3(3):221-2. PubMed ID: 12762969
[No Abstract] [Full Text] [Related]
17. Comment on: Evans JMM, Ogston SA, Emslie-Smith A, Morris AD (2006) risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49:930-936.
Tayek JA
Diabetologia; 2006 Nov; 49(11):2807-8. PubMed ID: 16955252
[No Abstract] [Full Text] [Related]
18. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
Standl E; Schnell O
Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474
[No Abstract] [Full Text] [Related]
19. Glucose supply and insulin demand dynamics of antidiabetic agents.
Monte SV; Schentag JJ; Adelman MH; Paladino JA
J Diabetes Sci Technol; 2010 Mar; 4(2):365-81. PubMed ID: 20307399
[TBL] [Abstract][Full Text] [Related]
20. [Glinide(s), sulfonylurea(s)].
Arakawa M; Hirose T
Nihon Rinsho; 2006 Nov; 64(11):2107-12. PubMed ID: 17087304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
